FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

Why it matters locally: The FDA's approval of this gene therapy could impact healthcare providers and patients across Kansas, offering a new treatment option for young children with sickle cell disease and beta thalassemia. Access to this specialized treatment, including its cost and availability, would be a key consideration for healthcare systems within the state.

---

The U.S. Food and Drug Administration (FDA) today announced a supplemental approval for Casgevy (exagamglogene autotemcel). This expanded approval permits the use of the gene therapy for patients aged two years and older. The therapy is indicated for individuals diagnosed with sickle cell disease (SCD) who experience recurrent vaso-occlusive crises (VOCs). Additionally, the approval covers patients with transfusion-dependent beta thalassemia (TDT).